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Background: Stepped care is recommended and implemented as a means to organise depression treatment.
Compared with alternative systems, it is assumed to achieve equivalent clinical effects and greater efficiency.
However, no trials have examined these assumptions. A fully powered trial of stepped care compared with
intensive psychological therapy is required but a number of methodological and procedural uncertainties
associated with the conduct of a large trial need to be addressed first.
Methods/Design: STEPS (Developing stepped care treatment for depression) is a mixed methods study to address
uncertainties associated with a large-scale evaluation of stepped care compared with high-intensity psychological
therapy alone for the treatment of depression. We will conduct a pilot randomised controlled trial with an embedded
process study. Quantitative trial data on recruitment, retention and the pathway of patients through treatment will be
used to assess feasibility. Outcome data on the effects of stepped care compared with high-intensity therapy alone
will inform a sample size calculation for a definitive trial. Qualitative interviews will be undertaken to explore what
people think of our trial methods and procedures and the stepped care intervention. A minimum of 60 patients with
Major Depressive Disorder will be recruited from an Improving Access to Psychological Therapies service and randomly
allocated to receive stepped care or intensive psychological therapy alone. All treatments will be delivered at clinic
facilities within the University of Exeter. Quantitative patient-related data on depressive symptoms, worry and anxiety
and quality of life will be collected at baseline and 6 months. The pilot trial and interviews will be undertaken
concurrently. Quantitative and qualitative data will be analysed separately and then integrated.
Discussion: The outcomes of this study will inform the design of a fully powered randomised controlled trial to
evaluate the effectiveness and efficiency of stepped care. Qualitative data on stepped care will be of immediate interest
to patients, clinicians, service managers, policy makers and guideline developers. A more informed understanding of
the feasibility of a large trial will be obtained than would be possible from a purely quantitative (or qualitative) design.
Trial registration: Current Controlled Trials ISRCTN66346646 registered on 2 July 2014.
Keywords: Stepped care, Major Depressive Disorder, Mixed methods, Feasibility studyBackground
Prevalence, impact and access
Depression is a long-term and relapsing condition and set
to become the third biggest cause of the global burden of
disease by 2030 [1]. Over three-quarters of all people who
recover from one episode will go on to have at least one* Correspondence: j.j.hill@exeter.ac.uk
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unless otherwise stated.more [2]. Lifetime prevalence has been estimated at 16.2%
and rates of co-morbidity are high [3-5]. In the UK, de-
pression and anxiety are estimated to cost the economy
£17 billion in lost output and direct healthcare costs annu-
ally, with a £9 billion impact on the Exchequer through
benefit payments and lost tax receipts [6].
Whilst there is a clear need for effective depression
treatment, access to treatment is poor: results from the
Adult Psychiatric Morbidity Survey 2007 indicate only
24% of people with common mental health problems. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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based psychological therapy [7]. For people with a severe
mental disorder, 35 to 50% of people in high-income
countries receive no treatment [8].
Stepped care
To maximise access, many clinical guidelines worldwide
recommend evidence-based psychological therapies for
depression to be delivered at low- and high-intensity
levels using a system called ‘stepped care’ [9-12]. Stepped
care requires that almost all patients start with an
evidence-based treatment of low-intensity as a first step
[13]. Progress is monitored systematically and patients
who do not respond adequately step up to a subsequent
treatment of higher intensity [14]. Low-intensity treat-
ments are usually defined as those treatments that require
less time from a healthcare professional than a conven-
tional treatment [15], although intensity may also mean
the time required of patients, cost and therapists’ level of
expertise. In England, stepped care has been adopted by
‘Improving Access to Psychological Therapies’ (IAPT)
services (www.iapt.nhs.uk) which have treated 500,000
patients annually since 2008. The majority of patients re-
ceive low-intensity treatment; around 30% are either allo-
cated directly or ‘stepped up’ to high-intensity psychological
therapy [16].
Uncertainties
Although stepped care is widely implemented in England,
based on their narrative review Bower and Gilbody
caution that the equivalence and efficiency of stepped care
are untested [14]. The central tenet of stepped care is that,
for most patients, low-intensity treatment is sufficient and
relatively few patients need to step up. If this holds, com-
pared with alternatives, stepped care may achieve equiva-
lent clinical outcomes at reduced cost and increase access
to treatment. However, there is insufficient evidence to
support this. In a systematic review and meta-analysis of
randomised controlled trials (RCTs) of stepped care, we
found a moderate effect of stepped care compared with
care-as-usual (n = 4580 patients, d = 0.34, 95% CI 0.20 to
0.48) [17] yet care-as-usual may not be the best trial com-
parator. To test equivalence and efficiency, a fully powered
clinical trial of stepped care compared with an alternative
system which has the potential to be as clinically effective
is required [14,17].
The National Institute for Health and Care Excellence
has made a specific recommendation to conduct a fully
powered trial of stepped care versus matched care for
depression [10]. Although the two systems may be as
clinically effective, there are no prognostic indicators, in-
cluding severity of depression itself, with sufficient
power to predict response to treatment and therefore
the specific treatment required for matched care [18]. Interms of severity, a recent individual patient data meta-
analysis of 2,470 patients with depression receiving low-
intensity treatment has shown that patients with severe
symptoms show at least as good clinical benefit from
low-intensity interventions as less severely ill ones [19].
Conversely, if cognitive behaviour therapy (CBT) as an
example of an intensive psychological therapy is pres-
ently considered the ‘gold standard’ treatment for de-
pression (effective against a number of comparators, in
patients with a range of severity of depressive symptoms,
in group and individual settings, and for both relapse
prevention and treatment of a current episode [10]), the
key question to test equivalence and efficiency becomes
“can CBT be ‘re-structured’ (as in stepped care) and
achieve equivalent patient outcomes at less cost, com-
pared with offering almost all patients high-intensity CBT
alone?” Compared with matched care, there are fewer un-
certainties associated with high-intensity CBT. Therefore,
in our opinion, the most appropriate and robust test of
the equivalence and efficiency of stepped care would be a
fully powered RCT against high-intensity (intensive) psy-
chological therapy alone.
The need for a mixed methods feasibility study
Whilst a fully powered RCT of stepped care compared
with intensive therapy is needed, a number of metho-
dological and procedural uncertainties currently prevent
such a trial: the appropriateness of potential trial methods
and procedures; recruitment and retention rates; the pro-
portion of patients who step up from low- to high-
intensity psychological therapy; an estimate of treatment
effects to inform a sample size calculation for the large
trial; and the acceptability of stepped care.
National IAPT data confirm that, despite the average
results cited above, rates of stepping up from low- to
high-intensity treatments varied from 0 to 50% of pa-
tients seen across services in the first year of their oper-
ation [20]. Services use different criteria to make clinical
decisions on initial stratification and stepping up [21].
This may reflect a lack of guidance on how stepped care
should be delivered; as yet, the optimal configuration of
system elements is unknown [14,17]. Data on current
practice will not reliably inform rates of stepping in a
fully powered trial.
With respect to acceptability, patients’ views of the
underpinning principles and implementation of stepped
care are uncertain [14]. Equally, we are unsure of the
views of administrative staff, therapists and other health
professionals who are required to deliver and support
stepped care [14]. If patients and/or therapists are strongly
opposed to stepped care this has implications for design
and perhaps feasibility of a large RCT. In the absence of
specific guidance on how to implement stepped care,
views on its operationalisation will be important to inform
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in a large clinical trial.
Commensurate with the Medical Research Council
framework for the development and evaluation of com-
plex interventions [22], all of the above uncertainties are
appropriate to address through piloting and in a feasibility
study [23]. An issue that arises is that quantitative data
alone will be inadequate. To understand what people think
of potential trial methods and procedures, qualitative data
will be important. Integrated with numeric data, they will
provide a richer understanding of the appropriateness of
those procedures. Moreover, to understand the acceptabil-
ity of stepped care, qualitative data are required. Merged
with quantitative data on treatment adherence, they may
help explain variability in patients’ therapeutic engage-
ment. Ultimately, the outcome of a feasibility study that
encompasses the collection and integration of quantitative
and qualitative data will be the information needed to de-
sign a large RCT of stepped care.
Study purpose
The purpose of this study will be to prepare the ground
for undertaking a fully powered RCT of stepped care com-
pared with high-intensity psychological therapy alone for
the treatment of depression in adults.
Objectives
Our specific objectives will be to: (1) gather enough infor-
mation on recruitment, retention, step ups and treatment
effects to design a fully powered clinical trial or to deter-
mine that such a trial is not feasible; and (2) explore pa-
tients’ and therapists’ views of stepped care and the ways
in which patients’ views relate to how much they engage
in therapy to inform a stepped care clinical protocol for a
proposed randomised trial.
Research questions
1. What is the quantifiable performance of recruitment
and retention methods which may be used in a fully
powered trial? (Objective 1)
2. What proportion of people who receive stepped care
step up from low-intensity to high-intensity treatment
or are discharged following low-intensity psychological
therapy? (Objective 1)
3. What is the variability in patient-related outcomes
following stepped care or intensive psychological
therapy alone and how do they correlate with pa-
tients’ baseline scores? (Objective 1)
4. To what extent are potential recruitment methods
considered appropriate by trial participants
(patients), study therapists and other health
professionals and administrators and how do
people’s views combine with numeric data on theperformance of trial recruitment methods?
(Objective 1)
5. How acceptable is stepped care to patients and
therapists and how do patients’ views explain
variability in the number of treatment sessions they
attend? (Objective 2)
Methods/Design
STEPS (Developing stepped care treatment for depression)
uses a mixed methods embedded design [24] in which
semi-structured interviews with patients, therapists and
other health professionals will be embedded within a pilot
RCT of stepped care versus intensive psychological the-
rapy alone for people with depression. Quantitative data
will be used to assess the feasibility of trial recruitment, re-
tention and clinical procedures and to inform the sample
size calculation that is required for a full-scale evaluation.
Semi-structured interviews will be embedded in the pilot
trial and undertaken concurrently to explore what trial
participants (patients) and others (for example, study
therapists) think of (i) trial methods and procedures and
(ii) the acceptability of the stepped care intervention. By
merging qualitative and quantitative data on trial methods
and procedures, we will develop a richer understanding of
their feasibility and appropriateness; through the integra-
tion of qualitative and quantitative data on the accepta-
bility of stepped care we will aim to explain variability in
patients’ treatment adherence.
Philosophical assumptions
By advocating a mixed methods design where the deci-
sion to incorporate qualitative and quantitative methods
is guided by the set of uncertainties (unanswered re-
search questions) that must first be addressed to inform
a full-powered RCT, we are guided by a pragmatic phil-
osophy: we give primary importance to the problem to
be addressed and how the information we collect will be
used [25]. We will also combine deductive and inductive
thinking; we will allow for a singular view and multiple
views of reality in how we come to understand and in-
terpret our findings; the motivation for the research is to
inform ‘real-world’ practice in the care of adults with de-
pression. In these respects, our views are consistent with
a pragmatic worldview [24].
Pilot randomised controlled trial
Setting and participants
We will recruit participants from an IAPT service. Eligible
participants will be aged 18 and older with Diagnostic and
Statistical Manual of Mental Disorders (DSM) Major
Depressive Disorder identified by standard clinical inter-
view (Clinical Interview Schedule – Revised) [26]. In line
with the current operating criteria for IAPT services to de-
termine who they treat and to reflect the pragmatic nature
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identify and exclude people at interview who are alcohol
or drug dependent, acutely suicidal or cognitively im-
paired, have bipolar disorder or psychosis/psychotic
symptoms. Participants will be eligible whether they are
in receipt of antidepressant medication or not. Patients
will subsequently be treated at the Mood Disorders
Centre Accessing Evidence-Based Psychological Therapies
(AccEPT) clinic facilities (see Trial Interventions section
below).
Randomisation, allocation concealment and blinding
Participants will be allocated in a 1:1 ratio to either the
stepped care or intensive psychological therapy arms
stratified according to their symptom severity on the
Beck Depression Inventory version I (BDI-I) [27] (BDI-I
minimal (0 to 9), mild (10 to 18), moderate (19 to 29),
severe (30 to 63)). Allocation will be minimised to maxi-
mise the likelihood of balance in stratification variables
across the two study arms. Concealment will be ensured
by use of an externally administered, password-protected
randomisation website and retaining a stochastic element
to the minimisation algorithm. The computer-based allo-
cation and website will be developed and maintained by
the accredited Peninsula Clinical Trials Unit, independent
of the trial. Participants’ details will be sent to the clinic
administrator to alert them to assign the patient a study
therapist and contact the patient to arrange treatment.
All research measures will be applied equally to both
groups of participants. At baseline, the study researcher
(JJH) will be blind to group allocation which will occur
after this assessment. At follow-up, the researcher will be
unblinded to allow her to interview patients (who have
been allocated to receive stepped care) on end-treatment;
interviews will occur prior to follow-up. Follow-up (and
baseline) data will be self-reported. In our opinion, the risk
of bias related to unblinding will be both minimal and
tolerable.
Recruitment
Patients will be recruited via an IAPT service serving a
city population. The service will write to all patients who
are offered an initial assessment appointment to invite
them to take part. A study summary sheet and permission
for researcher to contact form will accompany each letter.
Patients who complete and return their permission-to-
contact form will be telephoned by the study researcher
who will use a standard two-question case-finding instru-
ment for depression [28] to assess possible eligibility. Base-
line interviews will be arranged with potentially eligible
and willing participants. Interviewees will be sent a full
study information sheet and flow-chart. At interview,
the study will be explained in full and we will assess eli-
gibility using the Mini-Cog [29] to screen for cognitiveimpairment and the Clinical Interview Schedule (Revised)
[26]. If eligible, fully informed and consenting, patients will
enter into the study. Ineligible and/or unwilling patients will
continue with usual care at the IAPT service. We estimate
from our recent experience managing other National
Institute for Health Research mental health trials [30-32]
that we will need to send out 1,500 recruitment letters to
achieve the upper limit of our sample size (see below and
Figure 1).
Trial interventions
Clinical procedures in both arms of the feasibility trial are
CBT in both low- and high-intensity variants. All treat-
ments will be delivered at the Mood Disorders Centre
AccEPT Clinic facilities (http://www.exeter.ac.uk/moood-
disorders/acceptclinic/). The AccEPT Clinic is part of the
School of Psychology at the University of Exeter. It
provides psychological therapies as part of the Mood
Disorders Centre’s mission to develop, test and make ac-
cessible effective treatments for depression and other
mood disorders. Although the AccEPT Clinic has been
commissioned by the National Health Service, it is separ-
ate to and not an IAPT service; it has not previously deliv-
ered stepped care treatment for depression.
Stepped care
Stepped care will involve initial low-intensity CBT de-
livered using guided self-help (GSH) materials and,
dependent on treatment response, high-intensity CBT.
GSH material will be an offline version of the internet-
delivered Wellbeing Course developed by the Centre for
Emotional Health at Macquarie University, Sydney,
Australia (http://www.ecentreclinic.org/). In some cases,
the Centre for Emotional Health supplies course material
by post and patients are supported by a therapist via the
internet or by phone. Course effectiveness has been estab-
lished [33-35]. With the permission of Macquarie, we have
adapted the Wellbeing Course for UK patients; culturally
specific information and references have been replaced
with equivalent for the UK. Course material is otherwise
unchanged. We have consulted closely to replicate the
weekly delivery of the online course in how we will pro-
vide patients with pdf or paper documents. Each week for
5 weeks we will email or post patients a Lesson, Do-It-
Yourself (DIY) Guide, Stories and Additional Resources.
Lessons will be ‘core reading’. They will educate patients
about anxiety, low mood and depression; patients will read
about unhelpful thoughts and behaviours, physical symp-
toms of depression and, towards the end of the course,
relapse-prevention. DIY guides will provide patients with
the opportunity to further their understanding of and
begin to implement key concepts which are covered in
the Lessons. The Stories will describe two examples of
how others have learnt and practised those concepts.
Invited to participate (n=1500)
Assessed for eligibility (n=150)
Randomised (n=75)
Stepped Care (n=37) Cognitive Behaviour Therapy (n=38) 
Lost to follow up (n=7) Lost to follow up (n=8)
Analysed (n=30) Analysed (n=30)
Figure 1 Consolidated standards of reporting trials (CONSORT) diagram describing flow of patients through the study.
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provide further information on specific topics which may
help patients (for example, sleep, communication skills).
Patients will be supported by weekly contact with their
therapist involving up to five, 30-minute consultations.
The first consultation will be face-to-face; the remainder
will be by phone although we may accommodate patients’
specific requests for some or all of these to be face-to-face.
Stepped care participants’ progress will be monitored
using the Patient Health Questionnaire 9 (PHQ-9) [36].
At a sixth 30-minute consultation and following clinical
assessment and discussion with the participant, people
who show insufficient progress and/or who do not fall
below the accepted PHQ-9 threshold for recovery (≤9)
[37] will be offered high-intensity psychological therapy.
Participants who recover at this stage will only receive
low-intensity therapy (see Table 1).
High-intensity psychological therapy will be CBT de-
livered by therapists following a treatment protocol
based on the standard manuals published by Beck and
colleagues [38] and used in two of our other recent trials
[30,32]. Early sessions will focus on agreeing problems
to be addressed, therapeutic goals and learning about
the CBT model and techniques for behaviour change.
Patients will subsequently work on negative automatic
thoughts, maladaptive beliefs and, where indicated, under-
lying core beliefs. Later sessions will help patients anti-
cipate and practice managing their response to stressors
which could lead to future relapse. Specific CBT tech-
niques that may be used will include scheduling activityand mastery behaviours and the use of thought records.
All sessions will be face-to-face and consistent with
National Institute for Health and Care Excellence recom-
mendations for duration and frequency (that is, between 8
and 20, 50-minute consultations over a maximum of
16 weeks [10]).
Intensive psychological therapy alone
High-intensity psychological therapy for participants in
the control arm of the trial will be identical to the high-
intensity treatment for patients in stepped care except
that patients will only have intensive CBT; they will not
be offered GSH first.
Outcomes
Given this is a feasibility study with a range of different
aims to inform a fully powered evaluation of stepped care,
there is no single primary outcome measure. Rather a var-
iety of patient-related data will be collected at baseline and
8 months’ post-randomisation: severity of depressive
symptoms (BDI-I) [27], health-related quality of life (Short
Form Health Survey-36; SF-36) [39] and worry and anx-
iety (Generalised Anxiety Disorder-7; GAD-7) [40]. At
6 months’ post-randomisation we anticipate that treat-
ment for patients, including those who are randomised to
stepped care and step up to CBT, will be complete. We
will also collect data on the flow of participants through
the trial (that is, numbers of participants at each step) and
the number and proportion of people who step up and are
discharged from stepped care following low-intensity






Any 0-9 Patient is unambiguously below diagnostic
cut-off
Inform participant that treatment is ended
as a consequence of them no longer
meeting diagnostic criteria
Discharge
19-27 10-12 Patient is within suggested diagnostic
cut-off range and has made around
50% improvement
Discuss with participant and suggest
discharge due to good rate of progress
Step up or discharge
depending on participant’s
wishes
<19 10-12 Patient is within suggested diagnostic
cut-off range and has made less than
50% improvement
Discuss with participant and suggest
stepping up to increase progress further
Step up or discharge
depending on participant’s
wishes
Any 13-27 Patient is unambiguously above diagnostic
cut-off
Offer CBT to participant Step up
Criteria to determine if stepped care patients are discharged from treatment following guided self-help (GSH) or ‘step up’ to cognitive behaviour therapy (CBT).
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ment adherence and content; they will log all patient con-
tacts and record key themes covered at each treatment
session using an agreed, semi-structured form.
Sample size
A conventional power calculation is inappropriate for
the purpose of a pilot RCT [23,41]. Instead, we have cal-
culated the sample size required based on the margins
of error associated with the key parameters of interest,
specifically: recruitment and follow-up rates; the stand-
ard deviation of the primary outcome (and other con-
tinuous outcomes); and the correlation between baseline
and 6 month follow-up outcome scores, which can be
used to refine the sample size calculation for the fully
powered evaluation to take into account the added pre-
cision gained from adjusting for baseline scores when
comparing the follow-up outcome scores between the
trial arms.
We expect to approach a total of 1,500 patients to par-
ticipate in the feasibility trial. This is large enough to es-
timate a participation rate (as percentage of subjects
approached) of 5% with a margin of error of ±1.1% or to
estimate a participation rate of 10% with a margin of
error of ±1.5% based on 95% confidence intervals. How-
ever, if we need to approach a higher number of poten-
tial participants (2,000) and achieve a lower participation
rate of 2%, the associated margin of error will be ±0.7%
based on 95% confidence intervals.
If we assume the participation rate will be 5% of 1,500
people approached, then the feasibility trial would re-
cruit 75 participants. This is sufficient to: (i) estimate a
follow-up rate (as percentage of participants recruited)
of 80% with a margin of error of ±9%; (ii) estimate the
standard deviation of the continuous primary outcome
to within 22% of its true value based on the upper limit
of the 95% confidence interval; (iii) estimate the correl-
ation between the baseline and follow-up outcome
scores with a margin of error of 0.12 (based on the lowerlimit of the 95% confidence interval) if the true corre-
lation is 0.8. If we assume the participation rate will be
2% of 2,000 people approached, this is sufficient to: (i)
estimate a follow-up rate of 80% with a margin of error
of ±10.1%; and (ii) estimate the correlation between the
baseline and follow-up outcome scores with a margin of
error no greater than 0.13 (based on the lower limit of
the 95% confidence interval).
We consider the margins of error associated with the
recruitment of 75/1,500 people and 60/2,000 approached
to be acceptable and have, therefore, selected a range of
between 60 and 75 as our target sample size.Semi-structured interviews
Sample and setting
We will aim to interview all of the trial participants (pa-
tients) who are allocated to stepped care and to achieve
a minimum sample size of 24 patients with varied re-
ceipt of and adherence to low- and high-intensity ther-
apy within the stepped care protocol. All three of the
study therapists who will deliver trial treatments, the
AccEPT Clinic administrator, the IAPT team manager,
lead psychological wellbeing practitioner and administra-
tor will also be interviewed. Patient interviews will be
undertaken at AccEPT Clinic facilities, by phone or at
the participant’s home depending on interviewees’ pref-
erence. Therapist and other staff interviews will be held
at AccEPT or IAPT facilities.Recruitment
Patients’ informed consent to be interviewed will be de-
termined at trial participants’ baseline interview. On
completion of stepped care treatment, we will telephone
patients to establish that they are still willing to be inter-
viewed, remind them what will be involved and answer
any questions. For patients who remain willing, an inter-
view will be arranged no sooner than 48 hours later.
Confirmation of arrangements will be sent in writing.
Hill et al. Trials 2014, 15:452 Page 7 of 12
http://www.trialsjournal.com/content/15/1/452We will explain the opportunity to rearrange or cancel
the interview in our letter.
We will provide study therapists and the AccEPT ad-
ministrator with details of the interviews at a trial orien-
tation day at the start of the study at which we will also
establish their willingness to be interviewed. Interviews
will be arranged shortly before the end of their involve-
ment in the pilot RCT. IAPT staff will be invited to be
interviewed shortly before the end of the trial recruit-
ment period and interviews will be arranged on end-
recruitment.
Interview process and questions
Semi-structured interviews will be used to allow partici-
pants to describe their views in confidence. This approach
will enable us to explore the meaning of participants’ re-
sponses and to elicit more detail on themes which arise
during the interviews as well as to explore participants’
views on our pre-defined topics of interest [42].
Interview schedules will be adapted for patients, clini-
cians, the AccEPT administrator and IAPT staff. In this
way, we will ask people for their views and experience of
stepped care and our trial methods and procedures in
relation to their specific role or study involvement. To
find out about the acceptability of stepped care we will
invite people to describe what they understand by the
term ‘stepped care’. We will also explore their views and
experiences of its underpinning principles and imple-
mentation. For example, we will ask people what they
think about face-to-face versus telephone consultations,
starting with low-intensity treatment, monitoring and
(dependent on treatment response) progression to high-
intensity therapy. With respect to exploring the feasibility
and appropriateness of our trial procedures, we will ask
participants for their views and opinions of recruitment,
study management and data collection. We will aim to
identify procedures that facilitate the efficient running of
the trial but also any that are perceived to be problematic.
Interviews are expected to last up to 45 minutes and
will be audio-recorded with participants’ permission.
Analysis
First, we will analyse the quantitative trial data and the
qualitative data from the semi-structured interviews sep-
arately. Next, we will integrate both types of information
and conduct a mixed methods analysis [24].
Quantitative analysis
To address our first research question, “what is the quanti-
fiable performance of recruitment and retention methods
which may be used in a fully powered trial?”, we will use
count data to enumerate the flow of the participants
through the trial. We will express count data both as a
percentage of the total number of participants approachedand in relation to the preceding step in recruitment. We
will estimate margins of error for these parameters. For
each of the interventions, we will quantify the number of
participants who withdrew, could not be contacted or did
not provide 6 month follow-up data for another reason.
We will express numbers as a percentage of the total
number of participants in each of the stepped care or
high-intensity group. We will follow Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines [43] on
reporting the number of participants who exit the trial at
each step of recruitment and from whom we are unable to
collect follow-up data. We will quantify the number and
proportion of people who receive stepped care and step
up from low- to high-intensity treatment or are discharged
following low-intensity therapy (Question 2). To measure
the variability in patient-related outcomes following
stepped care or intensive psychological therapy and their
correlation with patients’ baseline scores (Question 3) we
will estimate the standard deviation around mean BDI-I,
GAD-7 and SF-36 scores at baseline and 6 months for
both groups. We will then estimate the correlation be-
tween participants’ scores on the BDI-I, GAD-7 and SF-36
at baseline and at 6 months. Quantitative data on the ac-
ceptability of stepped care (Question 5) will be analysed as
follows. For each of the interventions we will generate de-
scriptive statistics to describe the number of sessions
attended. We will quantify the number and proportion of
participants who declined any treatment, dropped out
early or completed treatment. For stepped care partici-
pants, we will quantify the number and proportion who
drop out prior to low-intensity therapy, before high-
intensity therapy having been stepped up, and during each
treatment step. Therapists’ thematic description of the
content of high-intensity CBT that is received by patients
in each of the intervention groups will be quantified and
compared. We will analyse session content data to assess
the extent to which GSH material and CBT are delivered
in line with our clinical protocol for CBT and guidance on
GSH.
All analyses will be on an intention to treat basis (that
is, we will analyse participants in their original assigned
groups). Emphasis will be on quantification and estima-
tion rather than hypothesis testing. We will not impute
missing data although we will report outcome data that
are missing in both intervention groups and, to the
extent that we are able, reasons for missing outcomes.
We will conduct all analyses using STATA v.11 (STATA,
StataCorp LP, College Station, TX, USA).
Qualitative analysis
Interviews on the acceptability of stepped care and the
appropriateness of trial recruitment methods will be
analysed to inform our answer to research Questions 4
and 5. The interviews will be transcribed verbatim and
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ductive and deductive approaches. The analysis of the
patient interviews will be iterative, moving between data
collection and analysis to test emerging theories. Ana-
lysis will therefore commence prior to the analysis of the
quantitative data from the pilot RCT. Transcripts will be
coded at the level of individual participants but analysed
thematically across the whole dataset as well as in the
context of each participant’s interview, using a constant
comparison approach [45]. Thematic frameworks will be
developed from a combination of interview topics and
data collected from participants. The data will be indexed
(applied to the thematic framework), charted, mapped and
interpreted to distil, structure and make sense of what
people say [46], the original transcripts being frequently
revisited to check and clarify contextual meaning . We will
identify and follow-up ‘deviant’ cases that do not fit into
emerging theories.
We will use NVivo version 9.0 (www.qsrinternational.
com/products_nvivo.aspx) to organise the data and en-
sure its systematic analysis. Preliminary findings will be
sent to interviewees for confirmation and correction.
Mixed methods data analysis and interpretation
Our mixed methods analysis will be guided by both the
nature of the quantitative and qualitative data that we ul-
timately obtain and the inferences that arise from our sep-
arate analysis of both. Consequently, the mixed methods
data analysis we eventually undertake may differ to the
analysis we propose. Analytical techniques have been pro-
posed based on methods summarised by Cresswell and
Plano Clark [24] and draw on examples of their use cited
therein [47-50].
For an improved understanding of the feasibility and
appropriateness of our trial procedures (research Question
4), we will merge qualitative data on appropriateness with
numeric data on the performance of recruitment methods
by presenting the qualitative and quantitative results to-
gether, side-by-side, in a summary table so that they can
be easily compared. We will also consider the use of a
joint display where qualitative themes are summarised in
relation to themes that arise from the quantitative data
(for example, on recruitment difficulties).
To investigate how patients’ views on the acceptability
of stepped care explain variability in the number of
treatment sessions they attend (research Question 5), we
will merge the quantitative and qualitative data we col-
lect from patients by developing typologies of their dif-
ferent views on acceptability. For each typology we will
present data on treatment adherence for patients for
whom the typology applies. We will also identify cat-
egories of patients defined by their treatment adherence
and explore similar and different views on acceptability
within and between categories. Finally, we will integratedata on acceptability and treatment adherence in a case-
oriented merged analysis display that will position cases
(patients) on a scale of treatment adherence along with
their qualitative data on acceptability.Ethical issues
We will conduct the trial in such a way to protect the
human rights and dignity of the participants as reflected
in the Helsinki Declaration [51]. Participants will not be
paid to participate. The study has been approved by the
National Research Ethics Service South West – Frenchay
(reference 13/SW/0140). National Health Service Re-
search and Development permission has been obtained
from Devon Partnership Trust (reference DPT 0258) to
identify and recruit patients. The School of Psychology
Ethics Committee at the University of Exeter has ap-
proved the study (reference 2012/500). To conform to
data protection and freedom of information acts, all data
will be stored securely and anonymised wherever pos-
sible. No published material will contain identifiable pa-
tient information.Obtaining informed consent from patients
We will determine informed consent in two stages. Po-
tential participants will be sent a one page study sum-
mary sheet and a form seeking their permission to be
contacted by a member of the study team, not at this
stage to give consent to taking part. Patients who are in-
terested in taking part will return their form to the study
team. Interested patients can also telephone the study
researcher. Potential participants will be telephoned by
the study researcher to assess their possible eligibility
and to answer any questions. For those who are willing
and possibly eligible, the study researcher will send a pa-
tient information sheet and arrange an interview. The
study summary and information leaflets will be pro-
duced using the current guidelines for researchers on
writing information sheets and consent forms, posted on
the Health Research Authority website (http://www.hra-
decisiontools.org.uk/consent/) and informed by our con-
sumer/lived experience user representatives. Full in-
formed consent will only be obtained at interview by the
study researcher. She will assess eligibility in full, fully
explain the study and answer outstanding questions. The
opportunity to participate in a semi-structured interview
will be optional; patients can consent to participate in the
pilot RCT only. We will explain that a decision not to be
interviewed will not affect patients’ participation in the
trial. We will establish consent to record and transcribe
interviews. The opportunity to withdraw from the pilot
trial and/or interview will be explained. The study re-
searcher will be fully trained and supervised by senior aca-
demic and clinically qualified staff. Communication and
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to monitor and act on participants’ wishes to withdraw.
Anticipated risks and benefits
No treatment will be withheld from participants taking
part in this study. Interventions comprise active psycho-
logical treatments with previously demonstrated efficacy
and no known iatrogenic effects. By participating in the
study, participants will also receive an intensive level of
monitoring such that any participants worsening or at
suicidal risk will be identified and directed to appropri-
ate care. The participant information leaflet will provide
potential participants with information about the pos-
sible benefits and risks of taking part in the trial. Partici-
pants will be given the opportunity to discuss this issue
with the study researcher prior to consenting. The study
researcher will inform the participants if new informa-
tion comes to light that may affect the person's willing-
ness to participate.
Managing risk of suicide
Inherent in the nature of the population under scrutiny is
the risk of suicide. We will follow good clinical practice in
monitoring for suicide risk during all clinical and research
appointments with study participants (patients). Where
any risk to participants due to expressed thoughts of sui-
cide is encountered, we will report these directly to the
general practitioner (with the participant’s expressed per-
mission), or if an acute risk is present will seek advice
from the general practitioner immediately and/or follow
locally established suicide management plans. All of the
study therapists and members of the research team will be
familiar with established protocols if a participant indi-
cates that they are having thoughts of self-harm or suicide.
Clinicians and researchers will be specifically trained in
risk assessment and management and supervised by expe-
rienced clinicians. Systems will be put in place to ensure
that senior academic and clinically qualified members of
the study team are notified should there be any risk to pa-
tients’ safety.
Patient and public involvement
The proposal for this study has arisen from a research
prioritisation process in the National Institute for Health
Research Collaboration for Leadership in Applied Health
Research and Care (CLAHRC) South West Peninsula
(PenCLAHRC, http://clahrc-peninsula.nihr.ac.uk/). Pen-
CLAHRC has a well-developed patient and public involve-
ment process through a funded group of representatives,
the Peninsula Public Involvement Group (PenPIG). Pen-
PIG members are involved in research topic identification
and prioritisation. The University of Exeter Mood Dis-
order Centre’s Lived Experience Group (LEG) advises on
all research activity in the centre. Patient and publicrepresentatives from both PenPIG and the LEG have been
involved at all stages in identification and preparation of
the proposal for this study and in the early work we have
conducted to underpin it.
Two members of the LEG will be involved in the de-
sign and conduct of the semi-structured interviews, spe-
cifically the development of the patient topic guide and
the analysis and interpretation of qualitative data,
including its implications for understanding both the ac-
ceptability of stepped care and the feasibility and appro-
priateness of trial procedures. We will follow national
good practice guidance for researchers on public in-
volvement in research and the paying of Patient and
Public Involvement (PPI) representatives at www.invo.
org.uk. We will also work with our PPI representatives
to ensure that our dissemination strategies are inclusive
and accessible to other people who use services.
Study oversight
An external advisor (academic psychiatrist) will be
appointed to provide the study team with independent
advice and guidance. The role of this person will include
reviewing serious adverse events which are thought to
be treatment related. This research forms part of the
first author’s (JJH) PhD programme of studies for which
she is supervised by DAR and WK.
Forecast execution dates
The preparatory period started in April 2013. Recruit-
ment is running from September 2013 for approximately
1 year. Follow-up and qualitative data will be collected
from April 2014 to March 2015. Data analysis and
reporting are forecast to take another 6 months. The
total duration of the study will be 24 months.
Discussion
This study will provide important information towards
the development and subsequent evaluation of stepped
care treatment for depression. Study outcomes will in-
form the design of a large clinical trial that will provide
much needed guidance on the effectiveness and effi-
ciency of stepped care to help policy makers, clinicians
and guideline developers decide on its merits as a sys-
tem for the organisation of depression treatment. We
anticipate that data on acceptability will be of immediate
interest to patients and those with responsibility for the
design, implementation and recommendation of systems
for the organisation of depression treatment.
A strength of the study design is that the methods
proposed are appropriate to the conduct of a feasibility
study. Our aim, specific objectives and research ques-
tions are commensurate with the definition of a feasibi-
lity study provided by the National Institute for Health
Research Trials and Studies (NETSCC) [52] endorsed by
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RCT sample size based on the key parameters of inter-
est: recruitment and retention. We will calculate the
variability of patient outcomes and their correlation with
baseline scores to inform a sample size calculation for a
fully powered RCT but we will not evaluate the out-
comes of interest. Indeed, we do not identify a primary
outcome measure. Rather, we have designed an RCT and
semi-structured interviews that will allow us to test un-
certainties associated with the conduct of a large stepped
care trial.
At a time when mixed methods are gaining ground in
health services research but can still be considered to be
under development [53,54], a further strength is that we
have made our commitment to this approach explicit
and clear. We have described our proposal in line with
recommendations for Good Reporting of a Mixed
Methods Study [55]. We have reached key decisions on
the level of interaction, priority, timing and mixing of
the quantitative and qualitative strands. This will be
reflected in our implementation of an embedded mixed
methods design [24]: quantitative and qualitative data
will be integrated (interact) prior to when we discuss the
results at the end of the study; we will collect and ana-
lyse qualitative data within a traditional quantitative
framework; we will undertake the pilot RCT and inter-
views concurrently; we will ‘mix’ the quantitative and
qualitative strands at the design level (that is, embed the
qualitative interviews within a pilot RCT for a more
complete understanding of trial methods and procedures
and to help explain variability in treatment attendance),
and also at the level of analysis. Ultimately, by implement-
ing an embedded mixed methods design, this study will
better prepare for a large clinical trial than would be pos-
sible from a purely quantitative (or qualitative) approach.
A potential weakness in our study design may be the
specific form of stepped care that we propose to deliver.
In the absence of specific guidance on how to imple-
ment stepped care or evidence on the optimal configur-
ation of system elements, we have developed a clinical
protocol that is true to stepped care principles (almost
all patients begin with low-intensity therapy, progress is
monitored systematically, only those who do not respond
‘step up’). Key components have been defined (for ex-
ample, stepping criteria). However, we do not know how
the effectiveness, efficiency or acceptability of stepped care
in this study compare with stepped care implemented in
other ways. This may have implications for a fully powered
evaluation of stepped care but also how data on the ac-
ceptability of stepped care are received. In our systematic
review of stepped care, we found considerable variety in
the implementation of stepped care but only one signifi-
cant difference between sub-groups of studies requiring
further investigation [17]. It is reasonable to conclude thatdifferences in the implementation of stepped care are not
necessarily associated with (statistically significant) differ-
ences in effectiveness; commonalities may be more im-
portant. Whilst patients’ views on the underpinning
principles of stepped care and how it is implemented will
be intertwined, we anticipate that data from the qualitative
interviews will inform our understanding of both. Patients,
therapists and others who are involved in deciding to rec-
ommend or implement stepped care may interpret data
on acceptability alongside the description of the interven-
tion received and consider how findings relate to their
own experience of stepped care implemented in similar or
different ways. Ultimately, the results of the current study
based on one form of stepped care will usefully inform the
design of a large clinical trial to compare stepped care
with high-intensity therapy alone for the treatment of
depression.Trial status
Recruitment commenced in September 2013 and is
ongoing.
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